Revolution Medicines, Inc. officer Stephen Michael Kelsey filed a Form 4 on November 18, 2026, disclosing option exercises and open-market share sales executed on November 16, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Kelsey exercised a stock option covering 27,160 shares of common stock at an exercise price of $18.56 per share on November 16, 2026.
  • Shares sold: A total of 27,160 shares were disposed of across six sale transactions at weighted average prices ranging from $166.7506 to $171.65 per share.
  • Post-transaction ownership: Following all reported transactions, Kelsey directly held 286,307 shares of common stock, which includes 65,613 restricted stock units.
  • 10b5-1 plan: According to the filing, all transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Stephen Kelsey on August 17, 2026.
  • Remaining options: Kelsey retains 108,640 fully vested stock options with an exercise price of $18.56, expiring March 1, 2032.
  • Role: The filing identifies Kelsey as Senior Advisor to the Chief Executive Officer at Revolution Medicines, Inc. (NASDAQ:RVMD).

Kelsey's November 16 Option Exercise and Sales Under 10b5-1 Plan

According to the Form 4 filed with the SEC on November 18, 2026, Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), exercised a fully vested stock option for 27,160 shares of common stock at $18.56 per share on November 16, 2026. The exercise brought his directly held share count to 313,467 shares before the subsequent sales.

The filing reports six separate sale transactions, all dated November 16, 2026, disposing of a combined 27,160 shares. The sales occurred across price ranges as follows: 11,542 shares at a weighted average of $166.7506 (range $166.14 to $167.13); 3,627 shares at $167.6619 (range $167.14 to $168.13); 8,039 shares at $168.6375 (range $168.15 to $169.13); 3,052 shares at $169.4561 (range $169.15 to $170.09); 700 shares at $170.3957 (range $170.22 to $170.63); and 200 shares at $171.65. The filing notes that each multi-trade transaction price reflects a weighted average, and the reporting person has undertaken to provide full per-trade detail upon request.

After all reported transactions, Kelsey's direct beneficial ownership stood at 286,307 shares, a figure the filing states includes 65,613 restricted stock units. His remaining unexercised stock options total 108,640, described in the filing as fully vested, with an exercise price of $18.56 and an expiration date of March 1, 2032. The Form 4 was signed by Jack Anders as attorney-in-fact for Stephen Michael Kelsey.

What Was Disclosed

The filing disclosed an option exercise of 27,160 shares at $18.56 and the same-day sale of those shares across six transactions under a pre-established Rule 10b5-1 plan, leaving Kelsey with direct beneficial ownership of 286,307 shares in Revolution Medicines, Inc.